All Outputs (73)

GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment (2017)
Journal Article
De Francesco, E., Sims, A., Maggiolini, M., Sotgia, F., Lisanti, M., & Clarke, R. (2017). GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment. Breast Cancer Research, 19(1), 129. https://doi.org/10.1186/s13058-017-0923-5

The G protein estrogen receptor GPER/GPR30 mediates estrogen action in breast cancer cells as well as in breast cancer-associated fibroblasts (CAFs), which are key components of microenvironment driving tumor progression. GPER is a transcriptional ta... Read More about GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.

A new mutation-independent approach to cancer therapy : inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis. (2017)
Journal Article
Ozsvari, B., Sotgia, F., & Lisanti, M. (2017). A new mutation-independent approach to cancer therapy : inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis. Aging, 9(10), 2098-2116. https://doi.org/10.18632/aging.101304

Here, we used MCF7 cells as a model system to interrogate how MYC/RAS co-operativity contributes to metabolic flux and stemness in breast cancer cells. We compared the behavior of isogenic MCF7 cell lines transduced with c-Myc or H-Ras (G12V), either... Read More about A new mutation-independent approach to cancer therapy : inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis..

Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer (2017)
Journal Article
Monti, D., Sotgia, F., Whitaker-Menezes, D., Tuluc, M., Birbe, R., Berger, A., …Martinez-Outschoorn, U. (2017). Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer. Seminars in Oncology, 44(3), 226-232. https://doi.org/10.1053/j.seminoncol.2017.10.001

Background

High oxidative stress as defined by hydroxyl and peroxyl activity is often found in the stroma of human breast cancers. Oxidative stress induces stromal catabolism, which promotes cancer aggressiveness. Stromal cells exposed to oxidativ... Read More about Pilot study demonstrating metabolic and anti-proliferative effects of in vivo anti-oxidant supplementation with N-Acetylcysteine in Breast Cancer.

Mitoketoscins : novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs). (2017)
Journal Article
Ozsvari, B., Sotgia, F., Simmons, K., Trowbridge, R., Foster, R., & Lisanti, M. (2017). Mitoketoscins : novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs). Oncotarget, 8(45), 78340-78350. https://doi.org/10.18632/oncotarget.21259

Previous studies have now well-established that epithelial cancer cells can utilize ketone bodies (3-hydroxybutyrate and aceto-acetate) as mitochondrial fuels, to actively promote tumor growth and metastatic dissemination. The two critical metabolic... Read More about Mitoketoscins : novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)..

Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer : companion diagnostics for cancer therapy (2017)
Journal Article
Sotgia, F., & Lisanti, M. (2017). Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer : companion diagnostics for cancer therapy. Oncotarget, 8(40), 66925-66939. https://doi.org/10.18632/oncotarget.19963

Here, we performed a systematic analysis to discover new biomarkers of overall survival and tumor progression in ovarian cancer patients. More specifically, we determined whether nuclear-encoded mitochondrial genes related to mitochondrial biogenesis... Read More about Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer : companion diagnostics for cancer therapy.

Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers : companion diagnostics for personalized medicine. (2017)
Journal Article
Sotgia, F., & Lisanti, M. (2017). Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers : companion diagnostics for personalized medicine. Oncotarget, 8(40), 67117-67128. https://doi.org/10.18632/oncotarget.19962

Here, we employed a bioinformatics approach to identify novel molecular determinants to predict tumor progression and overall survival in gastric cancer patients. In particular, we directly assessed whether nuclear-derived mRNA species encoding prote... Read More about Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers : companion diagnostics for personalized medicine..

Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients : use as companion diagnostics (2017)
Journal Article
Sotgia, F., & Lisanti, M. (2017). Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients : use as companion diagnostics. Oncotarget, 8(40), 68095-68107. https://doi.org/10.18632/oncotarget.19677

Here, we used an informatics-based approach to identify novel biomarkers of overall survival and tumor progression in non-small cell lung cancer (NSCLC) patients. We determined whether nuclear-encoded genes associated with mitochondrial biogenesis an... Read More about Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients : use as companion diagnostics.

Mitochondrial markers predict recurrence, metastasis and Tamoxifen-resistance in breast cancer patients : early detection of treatment failure with companion diagnostics (2017)
Journal Article
Sotgia, F., Fiorillo, M., & Lisanti, M. (2017). Mitochondrial markers predict recurrence, metastasis and Tamoxifen-resistance in breast cancer patients : early detection of treatment failure with companion diagnostics. Oncotarget, 2017(8), 68730-68745. https://doi.org/10.18632/oncotarget.19612

Here, we used a data-mining and informatics approach to discover new biomarkers of resistance to hormonal therapy in breast cancer. More specifically, we investigated whether nuclear-encoded genes associated with mitochondrial biogenesis can be used... Read More about Mitochondrial markers predict recurrence, metastasis and Tamoxifen-resistance in breast cancer patients : early detection of treatment failure with companion diagnostics.

Mitoriboscins : mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast (2017)
Journal Article
Ozsvari, B., Fiorillo, M., Bonuccelli, G., Cappello, A., Frattaruolo, L., Sotgia, F., …Lisanti, M. (2017). Mitoriboscins : mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. Oncotarget, 2017(8), 67457-67472. https://doi.org/10.18632/oncotarget.19084

The “endo-symbiotic theory of mitochondrial evolution” states that mitochondrial organelles evolved from engulfed aerobic bacteria, after millions of years of symbiosis and adaptation. Here, we have exploited this premise to design new antibiotics an... Read More about Mitoriboscins : mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast.

Targeting hypoxic cancer stem cells (CSCs) with Doxycycline : implications for optimizing anti-angiogenic therapy (2017)
Journal Article
implications for optimizing anti-angiogenic therapy. Oncotarget, 2017(8), 56126-56142. https://doi.org/10.18632/oncotarget.18445

Here, we report new mechanistic insight into how chronic hypoxia increases ‘stemness’ in cancer cells. Using chemical inhibitors, we provide direct experimental evidence that ROS production and mitochondrial biogenesis are both required for the hypox... Read More about Targeting hypoxic cancer stem cells (CSCs) with Doxycycline : implications for optimizing anti-angiogenic therapy.

Vitamin C and Doxycycline : a synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs) (2017)
Journal Article
De Francesco, E., Bonuccelli, G., Maggiolini, M., Sotgia, F., & Lisanti, M. (2017). Vitamin C and Doxycycline : a synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs). Oncotarget, 2017(8), 67269-67286. https://doi.org/10.18632/oncotarget.18428

Here, we developed a new synthetic lethal strategy for further optimizing the eradication of cancer stem cells (CSCs). Briefly, we show that chronic treatment with the FDA-approved antibiotic Doxycycline effectively reduces cellular respiration, by... Read More about Vitamin C and Doxycycline : a synthetic lethal combination therapy targeting metabolic flexibility in cancer stem cells (CSCs).

Hodgkin lymphoma : a complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment (2017)
Journal Article
Mikkilineni, L., Whitaker-Menezes, D., Domingo-Vidal, M., Sprandio, J., Avena, P., Cotzia, P., …Martinez-Outschoorn, U. (2017). Hodgkin lymphoma : a complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment. Seminars in Oncology, 44(3), 218-225. https://doi.org/10.1053/j.seminoncol.2017.10.003

Background

Twenty percent of patients with classical Hodgkin Lymphoma (cHL) have aggressive disease defined as relapsed or refractory disease to initial therapy. At present we cannot identify these patients pre-treatment. The microenvironment is v... Read More about Hodgkin lymphoma : a complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.

Current and prospective pharmacotherapies for the treatment of pleural mesothelioma (2017)
Journal Article
Bakker, E., Guazzelli, A., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. Expert Opinion on Orphan Drugs, 5(6), 455-465. https://doi.org/10.1080/21678707.2017.1325358

Introduction: Mesothelioma is a rare asbestos-linked cancer with an expected incidence peak between 2015–2030. Therapies remain ineffective, thus developing and testing novel treatments is important for both oncologists and researchers.


Areas co... Read More about Current and prospective pharmacotherapies for the treatment of pleural mesothelioma.

Mitochondrial “power” drives tamoxifen resistance : NQO1 and GCLC are new therapeutic targets in breast cancer (2017)
Journal Article
Fiorillo, M., Sotgia, F., Sisci, D., Cappello, A., & Lisanti, M. (2017). Mitochondrial “power” drives tamoxifen resistance : NQO1 and GCLC are new therapeutic targets in breast cancer. Oncotarget, 2017(8), 20309-20327. https://doi.org/10.18632/oncotarget.15852

Here, we identified two new molecular targets, which are functionally sufficient
to metabolically confer the tamoxifen-resistance phenotype in human breast cancer
cells. Briefly, ~20 proteins were first selected as potential candidates, based on
u... Read More about Mitochondrial “power” drives tamoxifen resistance : NQO1 and GCLC are new therapeutic targets in breast cancer.

Anti-CTLA-4 therapy for malignant mesothelioma (2017)
Journal Article
Guazzelli, A., Bakker, E., Krstic-Demonacos, M., Lisanti, M., Sotgia, F., & Mutti, L. (2017). Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy, 9(3), 273-280. https://doi.org/10.2217/imt-2016-0123

Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1. This... Read More about Anti-CTLA-4 therapy for malignant mesothelioma.

Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity (2016)
Journal Article
Bonuccelli, G., Peires-Pages, M., Ozsvari, B., Martinez- Outschoorn, U., Sotgia, F., & Lisanti, M. (2017). Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity. Oncotarget, 8(6), 9868-9884. https://doi.org/10.18632/oncotarget.14196

In this report, we systematically examined the role of telomerase activity in
lung and ovarian cancer stem cell (CSC) propagation. For this purpose, we indirectly
gauged telomerase activity, by linking the hTERT-promoter to eGFP. Using lung
(A549)... Read More about Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs) (2016)
Journal Article
Fiorillo, M., Lamb, R., Tanowitz, H., Cappello, A., Martinez‐Outschoorn, U., Sotgia, F., & Lisanti, M. (2016). Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs). Aging, 8(8), 1593-1607. https://doi.org/10.18632/aging.100983

Bedaquiline (a.k.a., Sirturo) is an anti‐microbial agent, which is approved by the FDA for the treatment of multi‐drug resistant pulmonary tuberculosis (TB). Bedaquiline is a first‐in‐class diaryl‐quinoline compound, that mechanistically inhibits the... Read More about Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs).

Cancer stem cell metabolism (2016)
Journal Article
Peiris-Pagès, M., Martinez-Outschoorn, U., Pestell, R., Sotgia, F., & Lisanti, M. (2016). Cancer stem cell metabolism. Breast Cancer Research, 18(55), https://doi.org/10.1186/s13058-016-0712-6

Cancer is now viewed as a stem cell disease. There is still no consensus on the metabolic characteristics of cancer stem cells, with several studies indicating that they are mainly glycolytic and others pointing instead to mitochondrial metabolism as... Read More about Cancer stem cell metabolism.

Cancer metabolism : a therapeutic perspective (2016)
Journal Article
Martinez-Outschoorn, U., Peiris-Pagés, M., Pestell, R., Sotgia, F., & Lisanti, M. (2016). Cancer metabolism : a therapeutic perspective. Nature Reviews Clinical Oncology, 14, 11-31. https://doi.org/10.1038/nrclinonc.2016.60

Awareness that the metabolic phenotype of cells within tumours is heterogeneous — and distinct from that of their normal counterparts — is growing. In general, tumour cells metabolize glucose, lactate, pyruvate, hydroxybutyrate, acetate, glutamine, a... Read More about Cancer metabolism : a therapeutic perspective.

Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells (2016)
Journal Article
Fiorillo, M., Lamb, R., Tanowitz, H., Mutti, L., Krstic- Demonacos, M., Cappello, A., …Lisanti, M. (2016). Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget, 7(23), 34084-34099. https://doi.org/10.18632/oncotarget.9122

Atovaquone is an FDA-approved anti-malarial drug, which first became clinically available in the year 2000. Currently, its main usage is for the treatment of pneumocystis pneumonia (PCP) and/or toxoplasmosis in immune-compromised patients. Atovaquone... Read More about Repurposing atovaquone : targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.